Project Grant K25CA297149
Award Date
5/7/25
Completion Date
4/30/30
Dollars Obligated
$172K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $267,298 to the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer with no established standard of care. The project aims to evaluate the sensitivity of TRCC cells to CDK4/6 inhibition, both alone and in combination with...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $368,288 to The Research Foundation for the State University of New York (RF SUNY) to identify and optimize small molecule inhibitors that disrupt the dimerization of TFE3 chimeric proteins. These TFE3 chimeric proteins play a key role in translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer. The proposed research aims to develop novel...
The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The five-year grant, running from December 1, 2024 to November 30, 2029, will support research to determine how specific configurations of the tricarboxylic acid (TCA) cycle metabolic pathway contribute to the development and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The research aims to...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $551,848 to the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the molecular mechanisms of developmental reprogramming in colorectal cancer (CRC). The key objectives are to identify regulators of fetal gene reactivation in CRC cells, determine if the transcription factor SOX9 directly controls fetal gene expression, and evaluate the...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $148,568.00 to St. Jude Children's Research Hospital Inc. to investigate the mechanism by which a gene essential for rhabdoid tumor viability regulates chromatin function. The project aims to gain mechanistic insights into the interplay between the SWI/SNF chromatin remodeling complex and the polycomb complex, which is disrupted in rhabdoid tumors. The research will use molecular...
The National Cancer Institute (NCI) awarded a $942,442 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant, effective September 1, 2024, supports research to identify the mechanisms driving rapid evolution of cancer genomes, with a focus on understanding the processes of chromothripsis and chromoplexy. The research aims to advance the fundamental knowledge of these catastrophic mutational...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
This Project Grant award of $893,184 from the National Cancer Institute's Cancer Research Manpower Program (CFDA 93.398) supports research to develop chimeric antigen receptor (CAR) T-cell therapies for renal cell carcinoma. The primary objectives are to: 1) Determine the effect of locally secreted VEGF blockade on CD70 CAR-T cell biology, function, and exhaustion; and 2) Evaluate the ability of CD70 CAR-T cells with VEGF blockade to modulate tumor proliferation, angiogenesis, and endothelial...
This $205,700 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at addressing the problem of rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance, and to test a novel combination therapy approach of DNA repair inhibition and targeted therapy to prevent resistance...
This $583,127 five-year Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to elucidate the mechanisms by which deficiency in the SMARCA4 gene promotes metastasis in lung adenocarcinoma. The key research objectives are to: 1) investigate how SMARCA4 deficiency regulates transcription and chromatin accessibility to drive metastasis, and 2) evaluate the therapeutic potential of...